Wave Life Sciences Ltd. recently announced that it will launch two key clinical trials for incretin-based adjuvant therapies in 2026: the Inlight study and the phase IIa trial of the new WVE-007.

This strategic initiative marks a crucial step for the company in the field of metabolic disease treatment. The newly launched trial will focus on evaluating the safety and effectiveness of its innovative therapy when combined with existing incretin-based drugs. Through this combination therapy approach, the company aims to explore more optimized treatment pathways for metabolic diseases and offer new options for patients. The launch plan for this trial highlights Wave Life Sciences' ongoing commitment and innovative strategy in the area of metabolic diseases. As the trial progresses toward 2026, the related research findings are expected to bring new breakthroughs for the treatment of metabolic diseases.